Teva Pharmaceutical Industries Limited reports developments across its global pharmaceutical business, including complex generic medicines, biosimilars, pharmacy brands, and innovative medicines in neuroscience and immunology. News commonly covers financial results, investor conference presentations, R&D updates, regulatory milestones, and product or patient-support launches tied to brands and candidates such as UZEDY, PONLIMSI, and proposed biosimilars.
As an Israel-based issuer with ADSs traded under TEVA, company updates also address ADR-relevant investor communications, operating outlook materials, partnerships, and strategy around a generics platform supporting a broader biopharmaceutical portfolio.
Teva (NYSE:TEVA) reported new data on AUSTEDO and AUSTEDO XR for tardive dyskinesia. Real-world IMPACT-TD results showed AIMS score reductions in all participants with mild TD at three months and better daily functioning. Three-year RIM-TD data indicated rising response rates with sustained treatment, while caregiver education efforts improved TD discussions and diagnoses.
Teva (NYSE:TEVA) reported new real-world survey data on AUSTEDO and AUSTEDO XR in Huntington’s disease (HD) chorea. The decentralized myHDstory study found HD chorea frequently disrupted social life, emotional wellbeing, daily activities and vocational/recreational life for both patients and caregivers before treatment.
Among patients taking AUSTEDO or AUSTEDO XR, 74% reported improved chorea movements, with 60–71% reporting quality-of-life gains across domains and over 85% noting better daily activities and social goals. Seventy-seven percent of caregivers reported improvements in social and emotional wellbeing goals as chorea impact declined.
Teva (NYSE: TEVA) launched AHZANTIVE (aflibercept), an EMA-approved biosimilar to Eylea, across several European markets, including France, Germany, Spain and The Netherlands.
The pre-filled syringe launch, begun in May 2026, supports Teva’s Pivot to Growth strategy and expands its ophthalmology biosimilars portfolio.
Teva (NYSE:TEVA) announced that President and CEO Richard Francis will take part in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026, at 8:00 A.M. Eastern Time.
Investors can access a live webcast and 30-day replay via Teva’s investor relations website.
Teva (NYSE: TEVA) and Medincell (Euronext: MEDCL) announced EMA acceptance of the Marketing Authorization Application for olanzapine long-acting injectable TEV-‘749 to treat adult schizophrenia.
The investigational subcutaneous injection is given every four weeks and is supported by a Phase 3 program, including SOLARIS.
TEV-‘749 uses Medincell’s SteadyTeq copolymer technology for controlled drug release and has shown efficacy, a systemic safety profile, and exposure consistent with oral olanzapine. TEV-‘749 is not approved by any regulatory authority worldwide.
Teva (NYSE:TEVA) and Medincell announced that the European Medicines Agency has accepted the Marketing Authorization Application for olanzapine long-acting injectable TEV-‘749 to treat schizophrenia in adults.
TEV-‘749 is a subcutaneous, once-every-four-weeks formulation supported by a Phase 3 program and is not yet approved anywhere.
Teva (NYSE:TEVA) reported that Fitch upgraded its corporate credit rating to investment grade BBB- with a stable outlook, up from BB+. Fitch also raised ratings on Teva’s senior unsecured debt and credit facilities to BBB-.
Fitch cites improved financial flexibility, a shift toward higher-margin innovative and biosimilar products, and expected growth driven by AUSTEDO, AJOVY, UZEDY and future launches such as olanzapine LAI, subject to regulatory approval. Teva remains rated BB+ (stable) by S&P and Ba1 (positive) by Moody’s.
Teva (NYSE:TEVA) reported new IMPACT-TD Registry data on adults with mood disorders and tardive dyskinesia (TD). Among young adults 18-29 (n=13), 85% had moderate to severe TD impact, yet only 23% were formally diagnosed, highlighting diagnostic gaps.
The 3-year, Phase 4, real-world registry includes 611 adults with TD; this analysis covered 211 with mood disorders not on VMAT2 inhibitors. Adults under 60 showed pronounced psychological effects, and patients waited on average over 3.5 years from first involuntary movements to TD diagnosis.
Teva (NYSE: TEVA) announced that Eric Hughes, EVP of Global R&D and Chief Medical Officer, will present at the BofA Securities Health Care Conference on May 12, 2026 at 9:20 A.M. PT / 12:20 P.M. ET. Live webcasts will stream from Teva’s investor relations site; archived webcasts will appear within 24 hours and remain available for up to 30 days.
Teva (NYSE: TEVA) published its 2025 Healthy Future Report highlighting sustainability and access-to-medicine achievements, including meeting all sustainability-linked bond targets totaling about $7.5 billion.
Key metrics: nearly 8 million people reached via product donations; 39% reduction in Scope 1–2 GHG since 2019; 32% reduction in Scope 3 since 2020; $36.4 billion in healthcare savings from generics across 21 countries; and >99% employee compliance training completion.